drugset
drugset / Trial / NCT04559971

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

NCT04559971 ↗

Phase 0 Completed 24 enrolled Silence Therapeutics GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and tolerability of SLN124 in healthy volunteers.

Timeline

Start
2020-09-03
Primary completion
2021-03-23
Completion
2021-03-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SLN124 Small interfering RNA (siRNA) 1 mg/kg Subcutaneous
Subject SLN124 Small interfering RNA (siRNA) 3 mg/kg Subcutaneous
Subject SLN124 Small interfering RNA (siRNA) 4.5 mg/kg Subcutaneous

Indications

No indication recorded.